pemetrexed + cisplatin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pleural Neoplasms
Conditions
Pleural Neoplasms
Trial Timeline
Sep 1, 2003 → Feb 1, 2008
NCT ID
NCT00087698About pemetrexed + cisplatin
pemetrexed + cisplatin is a phase 2 stage product being developed by Eli Lilly for Pleural Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00087698. Target conditions include Pleural Neoplasms.
What happened to similar drugs?
0 of 4 similar drugs in Pleural Neoplasms were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00040625 | Pre-clinical | Completed |
| NCT01000480 | Phase 2 | Completed |
| NCT00887549 | Phase 2 | Completed |
| NCT00895648 | Phase 2 | Terminated |
| NCT00475657 | Phase 2 | Terminated |
| NCT00447421 | Phase 1/2 | Terminated |
| NCT00415168 | Phase 2 | Completed |
| NCT00386815 | Phase 2 | Completed |
| NCT00374868 | Phase 1/2 | Completed |
| NCT00259285 | Phase 2 | Terminated |
| NCT00251550 | Phase 1/2 | Completed |
| NCT00191308 | Phase 2 | Completed |
| NCT00320515 | Phase 1/2 | Completed |
| NCT00190801 | Phase 2 | Completed |
| NCT00087698 | Phase 2 | Completed |
Competing Products
20 competing products in Pleural Neoplasms